Entresto and Xalatan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Entresto (sacubitril; valsartan) and Xalatan (latanoprost). Common drug interactions include blood creatine phosphokinase increased among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Entresto and Xalatan. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Entresto?

Entresto has active ingredients of sacubitril; valsartan. eHealthMe is studying from 126,628 Entresto users. Check the latest studies of Entresto.

What is Xalatan?

Xalatan has active ingredients of latanoprost. It is often used in glaucoma. eHealthMe is studying from 25,550 Xalatan users. Check the latest studies of Xalatan.

On Aug, 10, 2026

26 people who take Entresto and Xalatan together, and have interactions are studied.

What are the common drug interactions of Entresto and Xalatan, by gender? *:

female:

Blood creatine phosphokinase increased
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
Hypokalaemia (low potassium)
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Amaurosis (partial or total blindness without visible change in the eye)
Cardiomyopathy (weakening of the heart muscle)
Fracture
Hyperkalaemia (damage to or disease of the kidney)
Hypervigilance

male:

Dyspnoea (difficult or laboured respiration)
Blood pressure decreased
Death
Dysstasia (difficulty in standing)
Pulmonary oedema (fluid accumulation in the lungs)
Sinus node dysfunction (a group of abnormal heart rhythms)
Speech disorder
Blood glucose increased
Cardiac disorder
Cardiac failure chronic

What are the common drug interactions of Entresto and Xalatan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Cardiac failure
Dyspnoea (difficult or laboured respiration)
Dysstasia (difficulty in standing)
Energy increased
Hyperkalaemia (damage to or disease of the kidney)
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
Hypokalaemia (low potassium)
Sinus node dysfunction (a group of abnormal heart rhythms)
Speech disorder
Weight increased

What are the existing conditions these people have? *

Cardiac Failure: 7 people, 26.92%
High Blood Pressure: 5 people, 19.23%
Stress And Anxiety: 3 people, 11.54%
Nausea (feeling of having an urge to vomit): 3 people, 11.54%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 2 people, 7.69%
Anal Erosion: 2 people, 7.69%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 7.69%
Ejection Fraction Abnormal (abnormality in percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat): 2 people, 7.69%
Eye Disorder: 2 people, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Entresto and Xalatan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously